161. Familial benign chronic pemphigus
[
4 clinical trials,
7 drugs（DrugBank:
1 drug),
1 target gene / 20 target pathways ]
Searched query = "Familial benign chronic pemphigus", "Benign familial pemphigus", "Hailey Hailey disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-000373-80-FR | 24/05/2018 | 23 July 2018 | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease | A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101 | Darier’s Disease or Hailey-Hailey Disease MedDRA version: 20.0 Level: LLT Classification code 10011860 Term: Darier's disease System Organ Class: 100000004850 MedDRA version: 20.1 Level: LLT Classification code 10019029 Term: Hailey-Hailey disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: LX3305 250 mg capsule Product Code: LX3305 Pharmaceutical Form: Capsule INN or Proposed INN: None CAS Number: 1078151-47-9 Current Sponsor code: LX3305 Dihydrate Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Dermecular Therapeutics, Inc. | Authorised | Female: yes Male: yes | 40 | Phase 1;Phase 2 | France | |||
| 2 | NCT02782702 | September 2015 | 10 December 2018 | Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. | Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier | Hailey-Hailey Disease;Darier Disease | Drug: Botulism Toxin Treatment | University Hospital, Toulouse | Not recruiting | 18 Years | N/A | All | 30 | Phase 1 | ||
| 3 | EUCTR2013-004562-33-IT | 17/12/2013 | 19 February 2018 | PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS | PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS | SYMPTOMATIC HHD PATIENTS MedDRA version: 16.1 Level: LLT Classification code 10019029 Term: Hailey-Hailey disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: SCENESSE Product Name: SCENESSE Pharmaceutical Form: Implant | ISTITUTI FISIOTERAPICI OSPITALIERI | Authorised | Female: yes Male: yes | 10 | Phase 2 | Italy | |||
| 4 | JPRN-UMIN000010191 | 2013/04/01 | 2 April 2019 | The examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey disease | Drier's disease Hailey-Hailey disease | celecoxib | Juntendo university gradurate school of medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan |